Subtopic Deep Dive
Prognostic Biomarkers in Small Cell Lung Cancer
Research Guide
What is Prognostic Biomarkers in Small Cell Lung Cancer?
Prognostic biomarkers in small cell lung cancer are measurable indicators such as circulating tumor cells, circulating tumor DNA, DLL3 expression, and lactate dehydrogenase levels that predict patient survival and treatment response.
Research validates circulating tumor cells (CTCs) and CTC clusters (CTM) as prognostic markers in small cell lung cancer (SCLC) patients. Hou et al. (2012) demonstrated CTCs ≥50 per 7.5 mL blood predict poor survival (832 citations). Studies explore molecular characteristics of CTCs for personalized therapy stratification.
Why It Matters
Prognostic biomarkers enable patient stratification for clinical trials and guide therapeutic decisions in SCLC, which has poor prognosis with 5-year survival under 10%. Hou et al. (2012) showed CTC counts and CTM presence correlate with overall survival, allowing real-time monitoring without invasive biopsies. Yu et al. (2011) highlighted CTC isolation techniques supporting liquid biopsy applications in aggressive cancers like SCLC (1092 citations). These markers personalize immunotherapy and chemotherapy responses, as noted in lung cancer management guidelines (Travis et al., 2011, 4761 citations).
Key Research Challenges
Rare CTC Isolation
Circulating tumor cells in SCLC are rare events mixed with blood components, complicating isolation and characterization. Yu et al. (2011) identified technological challenges in CTC enrichment from primary and metastatic tumors (1092 citations). Accurate detection requires high-sensitivity methods for prognostic utility.
Molecular Heterogeneity
CTCs and CTM exhibit molecular variability predicting differential survival outcomes in SCLC. Hou et al. (2012) reported distinct gene expression in CTC clusters versus single cells, linking to poor prognosis (832 citations). Standardizing molecular profiling remains difficult across patients.
Validation in Trials
Translating CTC-based biomarkers from observational studies to prospective SCLC trials faces reproducibility issues. Krebs et al. in Hou et al. (2012) validated CTCs as surrogate endpoints but noted needs for larger cohorts. Integrating with LDH and DLL3 levels requires multi-marker validation.
Essential Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa, Shaker A. Mousa · 2016 · Translational Lung Cancer Research · 1.9K citations
Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung cancer (NSCLC) accoun...
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
Massimo Falconi, Barbro Eriksson, Gregory Kaltsas et al. · 2016 · Neuroendocrinology · 1.3K citations
be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare F-P-NETs (RFTs) considered together and as a separate category (Appendix 1 and...
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley et al. · 2021 · Journal of Thoracic Oncology · 1.3K citations
Circulating tumor cells: approaches to isolation and characterization
Min Yu, Shannon L. Stott, Mehmet Toner et al. · 2011 · The Journal of Cell Biology · 1.1K citations
Circulating tumor cells (CTCs) shed from primary and metastatic cancers are admixed with blood components and are thus rare, making their isolation and characterization a major technological challe...
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi, David S. Klimstra, Behnoush Abedi‐Ardekani et al. · 2018 · Modern Pathology · 1.1K citations
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marianne Pavel, Kjell Öberg, M. Falconi et al. · 2020 · Annals of Oncology · 1.1K citations
Reading Guide
Foundational Papers
Start with Travis et al. (2011, 4761 citations) for lung tumor classification context; Hou et al. (2012, 832 citations) for SCLC-specific CTC prognosis; Yu et al. (2011, 1092 citations) for CTC isolation techniques underpinning biomarker validation.
Recent Advances
Nicholson et al. (2021, 1317 citations) on WHO lung tumor updates; Lahiri et al. (2023, 924 citations) on lung cancer immunotherapy linking to biomarker-guided therapies.
Core Methods
CTC enumeration via CellSearch platform (Hou et al., 2012); molecular characterization by FISH/RT-PCR on isolated CTCs (Yu et al., 2011); survival analysis with Cox regression on biomarker levels.
How PapersFlow Helps You Research Prognostic Biomarkers in Small Cell Lung Cancer
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map SCLC biomarker literature from Hou et al. (2012, 832 citations), revealing connections to Travis et al. (2011, 4761 citations) on lung classifications. exaSearch uncovers DLL3 and LDH studies; findSimilarPapers expands from Yu et al. (2011) CTC methods.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Hou et al. (2012), then verifyResponse with CoVe checks claims against abstracts. runPythonAnalysis performs Kaplan-Meier survival curve plotting from CTC count data using pandas and matplotlib; GRADE grading assesses evidence strength for prognostic claims.
Synthesize & Write
Synthesis Agent detects gaps in CTC-DLL3 integration via contradiction flagging across papers. Writing Agent uses latexEditText for biomarker review drafting, latexSyncCitations for Hou et al. (2012) integration, and latexCompile for publication-ready output; exportMermaid visualizes CTC survival pathways.
Use Cases
"Analyze survival data from CTC counts in SCLC patients using Python."
Research Agent → searchPapers('Hou 2012 SCLC CTC') → Analysis Agent → readPaperContent → runPythonAnalysis (pandas survival curves from extracted data) → matplotlib plot of hazard ratios.
"Draft LaTeX review on prognostic biomarkers in SCLC with citations."
Synthesis Agent → gap detection on CTC/LDH → Writing Agent → latexEditText (review sections) → latexSyncCitations (Hou et al. 2012, Yu et al. 2011) → latexCompile → PDF with survival diagrams.
"Find code for CTC isolation analysis from SCLC papers."
Research Agent → searchPapers('CTC SCLC analysis code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → export of Python scripts for biomarker quantification.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ SCLC biomarker papers: searchPapers → citationGraph → GRADE grading → structured report on CTC prognosis. DeepScan applies 7-step analysis with CoVe checkpoints to validate Hou et al. (2012) claims against Travis et al. (2011). Theorizer generates hypotheses on DLL3-CTT integration from literature patterns.
Frequently Asked Questions
What defines prognostic biomarkers in SCLC?
Prognostic biomarkers in SCLC include CTC counts ≥50 per 7.5 mL blood and CTM presence predicting survival, as validated by Hou et al. (2012).
What methods isolate CTCs for SCLC prognosis?
Methods involve microchip-based or antibody capture for rare CTCs from blood, detailed in Yu et al. (2011) with applications to SCLC by Hou et al. (2012).
What are key papers on SCLC prognostic biomarkers?
Hou et al. (2012, 832 citations) on CTC/CTM in SCLC; Yu et al. (2011, 1092 citations) on CTC isolation; Travis et al. (2011, 4761 citations) on lung adenocarcinoma classification informing SCLC contexts.
What open problems exist in SCLC biomarkers?
Challenges include multi-marker validation of CTCs with DLL3/LDH, prospective trial integration, and molecular standardization across heterogeneous SCLC tumors.
Research Lung Cancer Research Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Prognostic Biomarkers in Small Cell Lung Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lung Cancer Research Studies Research Guide